Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen JAZZ PHARMACEUTICALS PLC stake
total: 670
Viking Global Investors JAZZ trades
- Total transactions:
- 13
- New positions:
- 2
- Sold out:
- 2
- Added:
- 5
- Reduced:
- 4
- Held since:
- 2017 Q1
- Held for:
- 9 quarters
- Latest activity:
- 2019 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any JAZZ PHARMACEUTICALS PLC (JAZZ) shares. To date, the estimated cost basis is nearly $154.79 for "buy" trades and estimated average "sell" price is $141.47. Viking Global Investors first purchased JAZZ in 2016 Q2, initially acquiring 618,862 shares. Ole Andreas Halvorsen later completely sold out the position and invested in JAZZ PHARMACEUTICALS PLC again in 2017 Q1. Since the initial investment in JAZZ PHARMACEUTICALS PLC (JAZZ), Viking Global Investors has made 12 more transactions.
When did Ole Andreas Halvorsen sell JAZZ PHARMACEUTICALS PLC (JAZZ)?
Ole Andreas Halvorsen sold off the entire JAZZ PHARMACEUTICALS PLC (JAZZ) position in 2019 Q2.
When did Ole Andreas Halvorsen buy JAZZ PHARMACEUTICALS PLC (JAZZ)?
Ole Andreas Halvorsen first invested in JAZZ PHARMACEUTICALS PLC (JAZZ) in 2016 Q2 at the reported quarter-end price of $141.31 per share.
What's the cost basis of Viking Global Investors's JAZZ stake?
The estimated cost basis for JAZZ PHARMACEUTICALS PLC (JAZZ) stake is around $154.79 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $154.79
- Weighted AVG sell price:
- $141.47
Ole Andreas Halvorsen's historical trades in JAZZ PHARMACEUTICALS PLC
13 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2019 Q2
|
0.00%
|
$142.95
|
-100% (-635,736)
|
|||
|
2019 Q1
|
0.52%
|
$142.95
|
-30.67% (-281,256)
|
|||
|
2018 Q4
|
0.65%
|
$123.96
|
-3.50% (-33,289)
|
|||
|
2018 Q3
|
0.88%
|
$168.13
|
+1.50% (+14,086)
|
|||
|
2018 Q2
|
0.92%
|
$172.30
|
+21.60% (+166,307)
|
|||
|
2018 Q1
|
0.70%
|
$150.99
|
-14.58% (-131,449)
|
|||
|
2017 Q4
|
0.75%
|
$134.65
|
-24.73% (-296,129)
|
|||
|
2017 Q3
|
1.13%
|
$146.25
|
+20.60% (+204,565)
|
|||
|
2017 Q2
|
1.04%
|
$155.50
|
+401.90% (+795,071)
|
|||
|
2017 Q1
|
0.13%
|
$145.13
|
new
|
|||
|
2016 Q4
|
0.00%
|
$121.48
|
-100% (-737,623)
|
|||
|
2016 Q3
|
0.39%
|
$121.48
|
+19.19% (+118,761)
|
|||
|
2016 Q2
|
0.37%
|
$141.31
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.